The Phase 3 EMERALD-3 trial has shown that a four-drug combination treatment can significantly delay disease progression in patients with unresectable hepatocellular carcinoma (HCC) who are eligible for embolization.
The study tested a combination of STRIDE therapy (tremelimumab and durvalumab), lenvatinib, and TACE, compared with TACE alone. Results showed that adding these therapies led to a meaningful improvement in progression-free survival. Early data also suggest a trend toward longer overall survival, although final results are still pending. Even the combination of STRIDE plus TACE, without lenvatinib, showed encouraging trends.
The safety of the combination was consistent with what is already known about each drug, with no new concerns identified. The trial included 760 patients from 22 countries. These findings suggest that using immunotherapy earlier in treatment, alongside standard procedures like TACE, could improve outcomes. Researchers will continue to track survival data and plan to submit the results to regulators to expand the use of this approach.